In July 2011, the FDA approved Xeomin for the treatment of fine lines and wrinkles in the forehead region. Xeomin is a botulinum toxin type A injectable, and it is the newest competitor to BOTOX® Cosmetic and Dysport.
Xeomin is similar to BOTOX® Cosmetic in many ways. Like BOTOX® Cosmetic, Xeomin works by paralyzing the facial muscles responsible for the formation of wrinkles. It also has similarities in regard to the length of time before you can see the full results (approximately one week) and the amount of time your results will last (approximately three to six months).
There is one main difference between these two options as well. Xeomin does not have any additives, so there is less of a risk of developing antibodies which may minimize the effectiveness of your treatment. However, it is important to remember that the longevity of Xeomin has not yet been tested, and this treatment does not have the long track record of success enjoyed by BOTOX® Cosmetic.
The risks associated with Xeomin are similar to the risks for BOTOX® Cosmetic, and they are equally rare. These include:
- The potential for the injectable to spread to other parts of the body
- Bruising at the injection site
- Allergic reactions to the treatment
At your initial consultation, our Denver aestheticians will explain the differences between these treatments in detail so that you can make a fully informed decision about which one will best meet your needs.
Please contact Facial Aesthetics today to schedule your free initial consultation. We serve patients in Denver, Colorado.